Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subunit Plague Vaccine (F1+rV) Safety and Immunogenicity
NCT02596308Phase 2Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Countries
- 1
01
Overview
Phase 2, randomised trial in plague, sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Immunogenicity after vaccination at Day 56 and Proportion of subjects reporting solicited adverse reactions at Day 35. Started Oct 2014; status: completed.
02
Conditions
plague
Beyond the preview
Go deeper on NCT02596308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596308.